Open Label Clinical Trial of Intravenous Crotoxin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Celtic Biotech Ltd.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Celtic Biotech Ltd Identifier:
First received: October 11, 2011
Last updated: November 28, 2011
Last verified: November 2011

The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported adverse effects associated with bolus administration.

Crotoxin has been shown to induce neurotoxic tolerance in animals allowing them to receive high doses associated with effective anti-tumor activity in the absence of adverse side effects.

Condition Intervention Phase
Drug: Crotoxin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration

Further study details as provided by Celtic Biotech Ltd:

Primary Outcome Measures:
  • Tolerability of intra-patient dose escalation [ Time Frame: 54 days ] [ Designated as safety issue: Yes ]
    Assess the safety and tolerability of Crotoxin administered intravenously to Stage IV cancer patients using intra-patient dose escalation procedure.

  • Confirmation of the induction of drug tolerance [ Time Frame: 54 days ] [ Designated as safety issue: Yes ]
    Confirm in a controlled phase I trial that human subjects can be made tolerant to intravenously administered Crotoxin thereby reducing the potential for adverse drug effects

Secondary Outcome Measures:
  • Assessment of drug efficacy [ Time Frame: 54 days ] [ Designated as safety issue: No ]
    Document any objective anti-tumour responses that occur in patients treated on this protocol.

Estimated Enrollment: 12
Study Start Date: September 2011
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Drug: Crotoxin
Intra patient dose escalation


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be adult patients with histologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists.
  2. Have an ambulatory PS (ECOG 0-1).
  3. Have tumour evaluation made within 28 days before study drug administration (patients with non measurable lesions according to the RECIST guidelines not previously irradiated are allowed to enter the trial).
  4. Have completed radiotherapy or chemotherapy or any other anticancer therapy (including experimental therapy) more than 4 weeks prior to enrolment into the trial and must have recovered from all acute side effects of these treatments
  5. Have a life expectancy greater than 3 months
  6. Have an age between 18 and 75 years
  7. Have normal marrow function with the following haematological parameters normal; Hb ≥10g/dl, WBC ≥4.0 x109/L, neutrophil count ≥ 2.0 x 109/L and platelets ≥100 x109 /L
  8. Have no medically significant impairment of cardiac or respiratory functions
  9. Have adequate hepatic function with Total bilirubin lower or equal to 1.5 x N and Transaminases lower or equal to 2.5 x N (lower or equal to 5 x N in case of liver metastasis).
  10. Have no history of prior severe allergic reactions to venoms
  11. Have Creatinine clearance ≥ 50 mL/min.
  12. Be on stable doses of any drugs which may affect hepatic drug metabolism or renal drug excretion (e.g.--non-steroidal anti-inflammatory drugs, barbiturates, narcotic analgesics, probenecid). Such drugs should not be initiated while the patient is participating in this study.
  13. Will agree to participate in the study prior to starting with any specific study procedure, after having signed written informed consent.

Exclusion Criteria:

  1. Pregnant or planning to become pregnant
  2. Known to have brain metastases or leptomeningeal involvement. CT-scan or MRI is not required to rule this out unless there is clinical suspicion of central nervous system involvement
  3. Have pleural effusion/ ascites, cystic lesions or bone metastases, as the only assessable lesions
  4. Receiving any other experimental or anti-cancer therapy within 30 days before first study drug administration (except antalgic radiotherapy and hormonotherapy)
  5. Have a history of other malignancies, except for patients with a cancer free interval of > 5 years after treatment completion, patients with prior history of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
  6. Have had recent major surgery (within 21 days).
  7. Have a recent history of weight loss > 10% of current body weight.
  8. Have serious intermittent medical illnesses which would interfere with the ability of the patient to carry out the treatment program.
  9. On chronic steroid medication (> 20mg/day)
  10. Have primary or paraneoplastic myasthenia gravis
  11. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01481532

Contact: Dorothy Bray, Ph.D. +33146334535

Hôpital Européen Georges Pompidou Recruiting
Paris, France, 75908
Contact: Jacques Medioni, MD    + 33 (1) 56 09 27 81   
Principal Investigator: Jacques Medioni, MD         
Sponsors and Collaborators
Celtic Biotech Ltd
Principal Investigator: Jacques Medioni, MD Hôpital Européen Georges Pompidou Paris, France
  More Information

No publications provided

Responsible Party: Celtic Biotech Ltd Identifier: NCT01481532     History of Changes
Other Study ID Numbers: CRTX01
Study First Received: October 11, 2011
Last Updated: November 28, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Celtic Biotech Ltd:
Antineoplastic agent processed this record on October 23, 2014